k7m2 cells  (ATCC)

Journal: bioRxiv

Article Title: Collagen targeting IL-12 combined with Doxorubicin enhances the anti-tumor effect against osteosarcoma

doi: 10.64898/2026.05.07.723520

Figure Lengend Snippet: The box plot of (a) collagen type I and (b) collagen type III expression in OS tissue compared with paired normal bone samples. (c) Collagen type I and III expression in both mouse (BVM03O and K7M2) and human OS. The cryosections were imaged by confocal microscopy. Nucleus and collagen type I or collagen type III were blue and red, respectively. Scale bars, 250 μm. The results are expressed as mean ± S.E.M. Statistical analysis was performed using an unpaired t-test for (a) and (b). *P < 0.05, **P < 0.01. N.S., not significant; PBS, phosphate-buffered saline.

Article Snippet: K7M2 cells (CRL-2836) were purchased from ATCC.

Techniques: Expressing, Confocal Microscopy, Saline

Journal: bioRxiv

Article Title: Collagen targeting IL-12 combined with Doxorubicin enhances the anti-tumor effect against osteosarcoma

doi: 10.64898/2026.05.07.723520

Figure Lengend Snippet: We inoculated mice with 3 × 10 6 BVM03O OS cells subcutaneously on the back skin and the mice were treated with PBS (i.v., n = 5), 416.6 pmol of CBD–IL-12 (i.v., n = 5), and 416.6 pmol of CBD–IL-12 + 2 mg/kg of Dox (i.v., n = 5) on day 35. Dox was additionally injected 3 and 6 days post initial treatment. Average tumor growth curve (a), individual tumor curves (b), and survival curves (c) are shown. We inoculated mice with 5 × 10 6 K7M2 OS cells subcutaneously on the back skin and the mice were treated with PBS (i.v., n = 4) and 416.6 pmol of CBD-IL-12 + 2 mg/kg of Dox (i.v., n = 3) once the tumor volume reaches 50 mm 3 . Dox was additionally injected on day 3 and day 6. Average tumor curve (d), individual tumor curves (e), and survival curves (f) are shown. The results are expressed as mean ± S.E.M. Log-rank test was used for (c) and (f) in the statistical analysis. *P < 0.05, **P < 0.01. N.S., not significant; PBS, phosphate-buffered saline.

Article Snippet: K7M2 cells (CRL-2836) were purchased from ATCC.

Techniques: Injection, Saline

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: αvβ3-targeted gas vesicles for ultrasound molecular imaging of tumors

doi: 10.3389/fbioe.2026.1808539

Figure Lengend Snippet: In vitro cell targeting studies. (A–C) Flow cytometry assay of bEnd.3 cells, K7M2 cells and B16-F10 cells incubated with FITC-Con, FITC-RGD or free RGD + FITC-RGD, respectively. Representative fluorescent microscope images of bEnd.3 cells (D) , K7M2 cells (F) and B16-F10 cells (H) incubated with FITC-Con-hGVs, FITC-RGD-hGVs or free RGD + FITC-RGD-hGVs. Green stands for FITC, and blue for cell nuclei stained with DAPI. Scale bar: 50 µm. (E,G,I) represent the quantitative analysis of the fluorescence intensity in (D,F,H) , respectively. *** for P < 0.001; **** for P < 0.0001.

Article Snippet: The K7M2 and B16-F10 cell lines, as well as mouse bEnd.3 endothelial cells, were obtained from ATCC.

Techniques: In Vitro, Flow Cytometry, Incubation, Microscopy, Staining, Fluorescence

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: αvβ3-targeted gas vesicles for ultrasound molecular imaging of tumors

doi: 10.3389/fbioe.2026.1808539

Figure Lengend Snippet: In vivo ultrasound molecular imaging of tumors. (A) Nonlinear contrast images of Con-hGVs and RGD-hGVs were obtained at various time points after intravenous injection in K7M2 osteosarcoma and B16-F10 melanoma tumor-bearing mice. Time–intensity curves of Con-hGVs and RGD-hGVs after intravenous injection in K7M2 osteosarcoma–bearing mice (B) , and corresponding tumor signal intensities at 1, 3, 5, 7, and 10 min post-injection (C) . Time–intensity curves of Con-hGVs and RGD-hGVs after intravenous injection in B16-F10 tumor–bearing mice (D) , and corresponding tumor signal intensities at 1, 3, 5, 7, and 10 min post-injection (E) .

Article Snippet: The K7M2 and B16-F10 cell lines, as well as mouse bEnd.3 endothelial cells, were obtained from ATCC.

Techniques: In Vivo, Imaging, Injection

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: αvβ3-targeted gas vesicles for ultrasound molecular imaging of tumors

doi: 10.3389/fbioe.2026.1808539

Figure Lengend Snippet: Immunofluorescence and quantitative analysis of tumors. (A,B) Vascular immunofluorescence images and their quantification were obtained 600 s following the intravenous injection of FITC-labeled Con-hGVs or RGD-hGVs in K7M2 osteosarcoma-bearing mice. (C) The corresponding 3D surface plot graphs are presented in. (D,E) Vascular immunofluorescence images and quantification were acquired 600 s following the intravenous injection of FITC-labeled Con-hGVs or RGD-hGVs in B16-F10 melanoma-bearing mice, with the corresponding 3D surface plot graphs displayed in (F) .

Article Snippet: The K7M2 and B16-F10 cell lines, as well as mouse bEnd.3 endothelial cells, were obtained from ATCC.

Techniques: Immunofluorescence, Injection, Labeling

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: αvβ3-targeted gas vesicles for ultrasound molecular imaging of tumors

doi: 10.3389/fbioe.2026.1808539

Figure Lengend Snippet: Biosafety analysis. (A) Hemolysis testing of RGD-hGVs at OD 500 = 0.5, 1.0, 1.5, 2.0, 2.5, or 3.0, using Triton X-100 as the positive control and PBS as the negative control (n = 3). (B) Viability of bEnd.3, K7M2, and B16-F10 cells following exposure to RGD-hGVs at OD 500 = 0.5, 1.0, 1.5, 2.0, 2.5, or 3.0 for 6 h (n = 3). (C) H&E histology of major organs from mice administered Con-hGVs (OD 500 = 3.0), RGD-hGVs (OD 500 = 3.0), or PBS; scale bar, 200 μm. (D–G) Serum markers of hepatic function and renal function measured 7 days after injection of PBS, Con-hGVs, or RGD-hGVs (n = 3).

Article Snippet: The K7M2 and B16-F10 cell lines, as well as mouse bEnd.3 endothelial cells, were obtained from ATCC.

Techniques: Positive Control, Negative Control, Injection